Researchers find patients' annual financial burden under Medicare Part D is 'too much too soon'

March 17, 2017

Medical advances have offered an increasing number of treatment options to patients with serious and chronic illnesses such as cancer, but these "specialty drugs" often come with a high price tag. A study released today by researchers at the Perelman School of Medicine at the University of Pennsylvania documents the patient out-of-pocket cost burden under Medicare prescription drug plans (known as Medicare Part D) and finds that despite having insurance, Medicare patients using specialty drugs paid thousands of dollars in out-of-pocket costs in a calendar year. Study authors also propose policy changes that would help patients better predict monthly bills for critical medications. The study appears online today in a special issue of The American Journal of Managed Care and was selected as the runner-up in the 2016 PAN Challenge, which asked researchers to offer "sustainable strategies for providing access to critical medications."

"Our study found that under current policy, Medicare patients with chronic myeloid leukemia, a form of blood cancer that can be treated with life-saving medications, had to pay an average of $2,452 for their medicines in January alone," said lead author Jalpa A. Doshi, PhD, an associate professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania. "That's almost twice the average monthly Social Security benefit."

Unlike most commercial insurance plans, there is no annual maximum out-of-pocket spending limit under Medicare Part D. The new study found that, in total, patients with paid an average of $6,322 over the course of a single year, and more than half of these payments were due in the first two months of the year. "Our findings underscore that policies need to pay attention not only to how much patients are required to pay during the year, but also to when they are required to pay it," Doshi said.

The study, which examined 2012 Medicare data for patients without low-income subsidies under Part D, also included patients receiving specialty drugs for rheumatoid arthritis or multiple sclerosis. Those patients had average annual out-of-pocket costs of $3,949 and $5,238, respectively, for all of their Medicare Part D-covered medications. Of note, half of people on Medicare have annual incomes below $24,150.

Doshi and colleagues have previously published studies showing that patients who are responsible for high out-of-pocket costs for specialty drugs are less likely to initiate treatment and more likely to skip or stop treatment. "Difficulty affording prescriptions is associated with inconsistent adherence, which could lead to adverse outcomes down the line," Doshi said. "It's important that we help patients manage their monthly costs so they can get the medications they need."

The new study also examined how changes recently proposed by the Medicare Payment Advisory Commission (MedPAC) would impact this real-world sample of Medicare beneficiaries. They found the changes would reduce the overall out-of-pocket cost burden for some patients and increase it for others, yet all would continue to be subject to substantial financial burden at the beginning of the year.

To address these high and variable monthly out-of-pocket costs, the authors outline relatively simple policy changes that would introduce both monthly and annual out-of-pocket spending limits, with the goal of providing consistency in monthly costs for their medications. "Energy companies already offer this sort of payment plan so that families aren't faced with unmanageable winter heating bills," Doshi said. "This approach is particularly important for many seniors who live on fixed incomes."

The authors also discuss the costs of their proposal. "The reality is that any proposed change needs to be financially sustainable," Doshi said. "We found that our suggested changes could be financed by an additional cost of only $1.96 per month, or $23.55 per year, per beneficiary."

Doshi presented the findings of the study at a Cost-Sharing Roundtable hosted by the Patient Access Network (PAN) Foundation in collaboration with The American Journal of Managed Care in Washington, DC on February 24.

Explore further: Studies show high out-of pocket costs limit access to lifesaving specialty drugs

Related Stories

Studies show high out-of pocket costs limit access to lifesaving specialty drugs

March 28, 2016
"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. But, insurers increasingly require ...

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients

October 3, 2016
Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North ...

Accountable Care Organizations reduced medical costs without increasing drug costs

March 13, 2017
A key component of the Affordable Care Act successfully saved Medicare $345 per person in medical costs in its first year without driving up prescription drug coverage costs, according to an analysis led by the University ...

Oral chemo still too expensive even after doughnut hole closes

December 8, 2015
Access to expensive oral chemotherapy drugs will still be out of reach for millions of Americans with Medicare coverage, even when one of the most touted reforms in health care coverage takes place in 2020. The analysis, ...

Kidney disease patients have higher out-of-pocket costs than stroke and cancer patients

January 17, 2017
Patients who have chronic kidney disease but are not on dialysis have higher out-of-pocket healthcare expenses than even stroke and cancer patients, according to a study by researchers at Loyola University Chicago and Loyola ...

Medicare spends billions on chronic kidney disease, study finds

March 29, 2016
(HealthDay)—Chronic kidney disease affects nearly 14 percent of Americans and costs Medicare billions of dollars a year, a new study reveals.

Recommended for you

'Man flu' may be real

December 11, 2017
The much-debated phenomenon of "man flu" may have some basis in fact, suggests an article published in the Christmas issue of The BMJ.

Full moon linked to increased risk of fatal motorcycle crashes

December 11, 2017
The full moon is associated with an increased risk of fatal motorcycle crashes in the United States, the United Kingdom, Canada and Australia, finds a study in the Christmas issue of The BMJ.

Social media trends can predict tipping points in vaccine scares

December 11, 2017
Analyzing trends on Twitter and Google can help predict vaccine scares that can lead to disease outbreaks, according to a study from the University of Waterloo.

Study suggests being proud may protect against falls in older people

December 11, 2017
Contrary to the old saying "pride comes before a fall", the opposite appears to be true, according to a study published in the Christmas issue of The BMJ.

Peppa Pig may encourage inappropriate use of primary care services

December 11, 2017
Exposure to the children's television series Peppa Pig may be contributing to unrealistic expectations of primary care and encouraging inappropriate use of services, suggests a doctor in the Christmas issue of The BMJ.

Women's sexual orientation linked to (un)happiness about birth

December 11, 2017
Unhappiness about a pregnancy or birth has been associated with negative health outcomes for mothers and babies. Yet, unhappiness about a pregnancy or birth has been understudied, particularly among sexual minority (non-heterosexual) ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.